(Q34434006)

English

Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

based on heuristic

1 reference

based on heuristic

author name string

Angiolo Gadducci

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Nicoletta Biglia

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Piero Sismondi

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Andrea Riccardo Genazzani

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Gynecological Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

343-360

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

The lifetime risk of developing breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Endocrine therapy for gynecological cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Obesity and breast cancer: a review of the literature.

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Molecular mechanisms of estrogen carcinogenesis

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Proliferation, cell cycle and apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

The insulin-like growth factor system in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Differential oxidant potential of carcinogenic and weakly carcinogenic estrogens: Involvement of metabolic activation and cytochrome P450.

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Free radical generation by redox cycling of estrogens

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Progress in chemoprevention of breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Design and methods of the Raloxifene Use for The Heart (RUTH) study

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Breast cancer prevention—clinical trials strategies involving aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Oral contraceptives and the risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Hormonal content and potency of oral contraceptives and breast cancer risk among young women

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Postmenopausal hormone therapy and mortality.

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Tibolone: a unique version of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Aromatase inhibitors in early breast cancer treatment

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Aromatase inhibitors in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Neoadjuvant endocrine therapy as a drug development strategy

1 reference

https://api.crossref.org/works/10.1080%2F09513590500128492

21 January 2018

Identifiers

10.1080/09513590500128492

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34434006&oldid=1952132030"